Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors denosumab - anti RANKL mAb Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03974100 (CGP24112301) Denosumab BioS Phase 3 522 Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density GP2411 60 mg/mL subcutaneous injection every 6 months ProliaⓇ 60 mg/mL subcutaneous injection every 6 months Postmenopausal women with osteoporosis Target Patients Read-out Milestone(s) 2022 Publication Study data publications expected for 2024 and beyond. The overall study design will be published at WCO and ECTS congresses 2020. 116 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine

View entire presentation